We describe a full-term infant with failed respiratory effort and decerebrate posturing following in utero exposure to paroxetine. All signs and symptoms associated with the paroxetine exposure were resolved by the second day of life. Upon discharge, the infant revealed a normal neurodevelopmental examination.
Introduction
Many women are vulnerable to psychiatric disturbances during the prenatal and the postpartum periods, necessitating the prescription of antidepressants. Safety information regarding the use of antidepressants in this patient population has been conflicting. Previous studies have favored selective serotonin reuptake inhibitor (SSRI) use over other antidepressants, such as tricyclic antidepressants (TCAs). 1 TCAs are less favorable owing to the high potential of anticholinergic effects, as well as their ability to cause postural hypotension. 1 Recently, the Food and Drug Administration (FDA) has determined that exposure to paroxetine in the first trimester of pregnancy may increase the risk for congenital malformations, particularly cardiac malformations. 2 Owing to the aforementioned reason, the FDA has requested that manufacturers change the pregnancy category for paroxetine from C to D and add warnings with regard to the use of this medication during pregnancy. 2 Medications are deemed Category C if animal reproduction studies have shown an adverse effect on the fetus, but there are no well-controlled trials in humans. When there is positive evidence of human fetal risk based on adverse reaction data from investigational, post-marketing experience, or studies in humans, medications are placed in pregnancy Category D. A withdrawal syndrome with TCAs and SSRIs has been reported in previous infants. 3 Reported signs of withdrawal syndrome include increased muscle tone, feeding disturbances, irritability, tremors/jitteriness, respiratory disturbances, increased reflexes and sleep disturbances. 4 Reports have suggested that paroxetine has a higher probability of causing a neonatal withdrawal syndrome than other SSRIs. 5 Case A 3420 g male infant was delivered by normal spontaneous vaginal delivery at 38 weeks' gestation by a 34-year-old, gravida 5, para 2, abortion 2, living 2, white single female. She had regular prenatal care with a past history significant of depression, following the death of her son. Home medications during pregnancy included paroxetine CR 37.5 mg once daily, olanzapine 1.25 mg once daily and clonazepam 1-2 mg once daily. She denied use of alcohol, tobacco or drugs. Prenatal labs were within normal limits; however, she did test positive for Group B streptococcus, which was treated with ampicillin before delivery. The mother was admitted to the hospital with contractions and artificial rupture of membranes approximately 7 h before delivery. Fluid was meconium stained. Before delivery, fetal monitoring showed a normal reactive infant. At birth, the infant failed to show respiratory effort and was intubated at 10 min of age; decerebrate posturing persisted for approximately 5 min, with a loading dose of 20 mg/kg of phenobarbital. Apgar scores were 2, 3, 5 and 6 at 1, 5, 10 and 15 min, respectively. At 1 h of age, the infant was slightly tachycardic, with a pulse of 140-190. Mild metabolic acidosis was noted on blood gas. Basic metabolic panel (BMP), at approximately 1 h of age, revealed hyponatremia, with a sodium level of 126 meq/l. A normal saline bolus was given and a septic workup was completed. Empiric therapy with ampicillin 340 mg i.v. twice daily and gentamicin 13 mg i.v. once daily was initiated. At 9 h of age, the infant's level of consciousness was improving. BMP was repeated at approximately 11 h of age, with a sodium level of 136 meq/l. Other electrolytes remained within normal limits. He was begun on total parenteral nutrition. He was extubated overnight, tolerating nasal canula, with good gas exchange and no apnea. Vital signs and electrolytes were within normal limits. A cerebrospinal fluid (CSF) examination was normal. Urine toxicological screen was positive for TCAs and negative for phencyclidine, benzodiazepines, cocaine, amphetamines, THC, opiates and barbiturates. Meconium drug screen was performed; results were negative for all agents.
A computerized tomography scan of the head was within normal limits, failing to show any seizure-producing focci. An electroencephalogram showed background suppression, secondary to phenobarbital. No evidence of underlying epileptic activity was noted. Head ultrasound was normal. Blood and CSF cultures were negative, including a viral culture for herpes. At approximately 24 h of age, all previous signs and symptoms diminished. Infant appeared well and there was no further seizure-like activity. Simalac with iron was started on post-natal day 2 and advanced without difficulty. At approximately 48 h of age, paroxetine toxicity was suspected. The mother confirmed that she last took her home medications 1 day before delivery. There was possible infant withdrawal in utero, resulting in failed respiratory effort upon delivery. The infant was weaned to room air on post-natal day 6. He was maintained in the Neonatal Intensive Care Unit (NICU) until post-natal day 13, to monitor for further withdrawal symptoms. Upon discharge, the infant revealed a normal neurodevelopmental examination.
Discussion
After completion of a differential diagnosis, this infant was determined to have neonatal drug withdrawal syndrome, secondary to paroxetine exposure. A neonatal abstinence scale was not used to assess this infant; however, the use of such a scale has since been implemented. Characteristic symptoms of this infant included hypotonia, irritability, feeding intolerance, sleep disturbances and respiratory failure. These symptoms were present for 24 h; however, the infant was kept under close observation for 1 week.
Shortly after birth, the infant experienced hypotonia, leading to a preliminary diagnosis of neonatal seizure disorder, which was not supported by further evaluation. Benzodiazepine withdrawal, secondary to maternal clonazepam use, was ruled out when a phenobarbital loading dose, given at birth, did not alleviate the symptoms. The diagnosis was further complicated by a positive urine drug screen for TCAs. Owing to the mother's previous olanzapine use, further investigation was conducted and information was obtained, indicating a potential for a false-positive TCA screen with olanzapine use. 6 Considering the multiple factors at hand, it was determined that the infant's symptoms were secondary to in utero exposure to paroxetine.
Clonazepam and olanzapine may have contributed to the clinical picture of this infant. According to the review published by Gentile in 2004, olanzapine has been associated with one case of unilateral dysplastic kidney, one case of Down's syndrome and one case of sudden infant death syndrome at 2 months. 7 There have been no reports of olanzapine-induced withdrawal syndromes in neonates. Paroxetine exposure was not considered in the initial differential diagnosis, potentially owing to lack of understanding of the withdrawal syndrome, despite the growing body of evidence. With the common use of antidepressants during pregnancy, education of physicians, nurses and parents is imperative.
